We came across a bullish thesis on CRISPR Therapeutics AG (CRSP ... Meanwhile, its allogeneic CAR-T therapies, CTX112 and CTX131, offer a low-cost, scalable approach to oncology, a market that ...

Elsewhere, CRISPR Therapeutics is developing other gene-editing medicines. It's working on a functional cure for type 1 diabetes. Meanwhile its CTX112, being developed to treat B-cell malignancies ...

The increased potency observed in CTX112 through novel edits has also raised expectations for its potential efficacy in autoimmune diseases, particularly systemic lupus erythematosus (SLE). In the ...

CRISPR Therapeutics AG, a gene editing company ... It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology ...